Sanofi Vaccines Joins $19.4 Million DLA Contract for Pharmaceuticals

Sanofi Vaccines US, located in Swiftwater, Pennsylvania, has recently been added to an existing multi-award contract with the Defense Logistics Agency (DLA). This collaboration focuses on the procurement of pharmaceutical products and has a total award value of approximately $19.4 million.

Contract Details

The DLA contract, officially known as SPE2D0-27-D-0001, stems from an original solicitation that was awarded on November 15, 2016. By adding Sanofi Vaccines US to this pool of suppliers, the agency expands its list of potential providers for government procurement needs.

Importance of Multi-Award Contracts

Multi-award contracts are crucial for the Defense Logistics Agency as they streamline the procurement process for federal customers. These arrangements facilitate the acquisition of essential pharmaceuticals under pre-established terms, enabling government entities to order supplies as needed.

By integrating Sanofi Vaccines US into this existing framework, the DLA enhances its capability to meet diverse procurement requirements, ultimately benefiting the healthcare organizations it serves.

Contract Value and Expectations

The reported value of the newly included contract is $19,449,682. However, it is important to note that this figure does not reveal specifics about individual pharmaceutical products, delivery timelines, or the exact funding allocated at this stage. Therefore, the stated value should not be seen as a guaranteed expenditure or order amount.

The inclusion of Sanofi Vaccines US signifies a strategic move in bolstering federal medical logistics. Pharmaceutical supply arrangements like this play an integral role in the procurement infrastructure used by government healthcare facilities to acquire necessary medical products.

This contract update represents a continuation of an ongoing supply agreement designed to support various government medical purchasing initiatives. The DLA Troop Support office, based in Philadelphia, Pennsylvania, oversees the contracting processes for this arrangement.

Broader Impact on Sanofi Vaccines US

For Sanofi Vaccines US, this addition opens doors to new federal procurement opportunities within the pharmaceutical and vaccine sectors. The company’s inclusion in the DLA contract not only signifies trust in their supply capabilities but also expands their potential customer base in the realm of government healthcare procurement.

As the landscape of pharmaceutical procurement continues to evolve, the consolidation of suppliers within existing contracts illustrates a proactive approach to ensuring that governmental agencies have a reliable source for their medical needs.